Search clinical trials for: Apatinib, Etoposide

Total 3565 results

Tianjin Medical University Cancer Institute and...

Unknown

A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy

Gastric Cancer

China
Qilu Hospital of Shandong University

Not yet recruiting

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Ovarian Cancer Recurrent
Xiaohua Wu MD

Not yet recruiting

Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

Relapsed Ovarian Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

Stage III Hepatocellular Cancer (CNLC Staging)

China
Hunan Cancer Hospital
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Recruiting

A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).

Hepatocellular Carcinoma | Immune Checkpoint Inhibitors

China
Peking University First Hospital

Not yet recruiting

Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma

Renal Cell Carcinoma
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial

Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

China
ShiYue Li

Unknown

Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer (CCA-MPLC)

Lung Cancer
Zhejiang University
Huashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Unknown

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

Hepatocellular Carcinoma | Liver Transplant

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Carcinoma, Non-Small-Cell Lung

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Harbin Medical University

Recruiting

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

Gastrointestinal Cancer | Immunotherapy | Targeted Therapy

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Sarcoma
Henan Cancer Hospital

Unknown

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Advanced Cancer | Mucosal Melanoma | Apatinib | SHR-1210

China
Beijing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

HER-2 Negatived Gastric Cancer

China
Shanxi Province Cancer Hospital

Unknown

Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer

Brain Metastases
Zhejiang Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

Gastric Cancer

China
Institut Paoli-Calmettes

Suspended

Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer (PIKHER2)

Breast Cancer

France
Changzhou Cancer Hospital of Soochow University

Completed

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (EASE)

Non-small Cell Lung Cancer

China
Augusta University
H. Jean Khoury Cure CML Consortium

Recruiting

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (ALERTCML)

Leukemia, Myeloid | Chronic Myeloid Leukemia, Chronic Phase | Adult CML | Leukemia,Myeloid, Chronic

United States
Wei Zhao
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Hematological Neoplasms

China
Xuanwu Hospital, Beijing

Recruiting

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

Chordoma | Chemotherapy Effect

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Apatinib Mesylate

Solid Tumor

China
Ruijin Hospital

Recruiting

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS)

Sarcoma

China
Sun Yat-sen University

Completed

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Recurrent Cervical Carcinoma | Metastatic Cervical Cancer

China
First Affiliated Hospital Bengbu Medical College

Unknown

Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer

Gastric Cancer | Apatinib | Biomarker

China
Tongji University

Unknown

Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Hepatocellular Carcinoma Resectable
Tianjin Medical University Second Hospital

Unknown

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

Small Cell Lung Cancer Extensive Stage

China
Peking University People's Hospital
Peking University Shougang Hospital; Peking University International Hospital

Withdrawn

Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial

Advanced Cancer | Soft Tissue Sarcoma Adult

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Advanced Gastric Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

NSCLC

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

China
HRYZ Biotech Co.

Recruiting

MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

Sarcoma

China
Elevar Therapeutics

Completed

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

Healthy

United States
Peking University Cancer Hospital & Institute

Unknown

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Melanoma

China
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Completed

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Wei Jiang
Wuzhou Red Cross Hospital; Laibin People's Hospital; Guangxi Naxishan Hospital; People's Hospital of Lingshan

Completed

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
First Affiliated Hospital Xi'an Jiaotong University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer (CCWSA/OAFLAG)

Locally Advanced Gastric Cancer

China
Guangxi Medical University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma
University Hospital, Bonn

Completed

Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children (HIT-REZ-2005)

Ependymomas | Recurrent Brain Tumors | Supratentorial PNETs | Medulloblastomas

Germany
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy

Non-small Cell Lung Cancer

China
Fudan University

Not yet recruiting

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Thyroid Cancer

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma (SHR-1210)

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Hepatocellular Carcinoma

China
Yan Li
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer

Breast Cancer
Hebei Medical University Fourth Hospital

Unknown

A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma

Refractory or Metastatic Esophageal Squamous Cell Carcinoma

China

3

Subscribe